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a b s t r a c t
Reactive oxygen species, when released under controlled conditions and limited amounts, contribute to
cellular proliferation, senescence, and survival by acting as signaling intermediates. In past decades there
has been an epidemic diffusion of nonalcoholic fatty liver disease (NAFLD) that represents the result of
the impairment of lipid metabolism, redox imbalance, and insulin resistance in the liver. To date, most
studies and reviews have been focused on the molecular mechanisms by which fatty liver progresses to
steatohepatitis, but the processes leading toward the development of hepatic steatosis in NAFLD are not
fully understood yet. Several nuclear receptors, such as peroxisome proliferator-activated receptors
(PPARs) α/γ/δ, PPARγ coactivators 1α and 1β, sterol-regulatory element-binding proteins, AMP-activated
protein kinase, liver-X-receptors, and farnesoid-X-receptor, play key roles in the regulation of lipid
homeostasis during the pathogenesis of NAFLD. These nuclear receptors may act as redox sensors and
may modulate various metabolic pathways in response to speciﬁc molecules that act as ligands. It is
conceivable that a redox-dependent modulation of lipid metabolism, nuclear receptor-mediated, could
cause the development of hepatic steatosis and insulin resistance. Thus, this network may represent a
potential therapeutic target for the treatment and prevention of hepatic steatosis and its progression to
steatohepatitis. This review summarizes the redox-dependent factors that contribute to metabolism
alterations in fatty liver with a focus on the redox control of nuclear receptors in normal liver as well as
in NAFLD.
& 2013 The Authors .Published by Elsevier Inc .
Contents
Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 953
Redox regulation of key enzyme activity in lipid metabolism in NAFLD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 953
Redox-dependent post-translational protein modiﬁcations in NAFLD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 955
Redox balance and insulin control of lipid metabolism in NAFLD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 956
Redox control of lipid metabolism by nuclear receptors in normal liver and NAFLD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 956
PPAR family . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 956
PGC-1 family . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 958
SREBP family . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 959
AMP-activated protein kinase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 959
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/freeradbiomed
Free Radical Biology and Medicine
0891-5849 & 2013 The Authors. Published by Elsevier Inc.
http://dx.doi.org/10.1016/j.freeradbiomed.2013.08.174
Abbreviations: ROS, reactive oxygen species; NR, nuclear receptor; FA, fatty acid; TAG, triacylglycerol; MCD, malonyl-CoA decarboxylase; ACC, acetyl-CoA carboxylase; FAS,
fatty acid synthase; SCD1, stearoyl-CoA desaturase-1; G-3-P, glycerol 3-phosphate; CPT-1, carnitine palmitoyl transferase 1; TCA, tricarboxylic acid; HMG-CoAR, 3-hydroxy-
3-methylglutaryl-CoA reductase; ER, endoplasmic reticulum; 4-HNE, 4-hydroxynonenal; NASH, nonalcoholic steatohepatitis; UCP-2, uncoupling protein 2; PPARα/γ/δ,
peroxisome proliferator-activated receptors α/γ/δ; PGC-1α/β, PPARγ coactivators 1α and 1β; SREBP, sterol-regulatory element-binding protein; AMPK, AMP-activated
protein kinase; LXR, liver-X-receptor; FXR, farnesoid-X-receptor; ACOX, acyl-CoA oxidase; SOD, superoxide dismutase; CAT, catalase; GSH, glutathione; FAT/CD36, FA
translocase; NRF, nuclear respiratory factor; mtTFA, mitochondrial transcription factor A; NAFLD, nonalcoholic fatty liver disease; FOX, forkhead box class; MAPK, mitogen-
activated protein kinase; CREB, cAMP-responsive element-binding protein; IRS, insulin receptor substrate; HC, hydroxycholesterol; NFE2L2, nuclear factor (erythroid-derived
2)-like 2; UPR, unfolded protein response; GPX, glutathione peroxidase; GST, glutathione S-transferase; GRx, glutathione reductase; ALA, α-lipoic acid
n Corresponding author. Fax: þ39 0881 741587.
E-mail addresses: g.serviddio@unifg.it, g.serviddio@gmail.com (G. Serviddio).
Free Radical Biology and Medicine 65 (2013) 952–968
Open access under CC BY license. 
Open access under CC BY license. 
Liver-X-receptor family and farnesoid-X-receptor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 960
Hepatic lipotoxicity: from low to high redox imbalance. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 961
Antioxidant defense mechanisms and lipid metabolism in NAFLD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 961
Antioxidant therapy in NAFLD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 961
Concluding remarks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 962
Acknowledgment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 962
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 962
Introduction
Oxidative stress, which accounts for the dysfunction or death of
hepatocytes and other liver cells, contributes to the pathogenesis
of acute and chronic liver diseases [1,2]. Even though reactive
oxygen (ROS)1 and nitrogen species are normally produced by the
metabolism of normal cells, in hepatic diseases an overproduction
of free radicals that overcomes the antioxidant defenses occurs,
inducing liver injury [3]. At high concentrations, free radicals are
dangerous for several cellular constituents. However, at low or
moderate concentrations, they may act as regulatory mediators in
signaling processes. Various sources of free radicals are implicated
and can be classiﬁed as mitochondrial, principally from Complexes
I and III, and extramitochondrial, such as cytochrome P450,
xanthine oxidase, nitric oxide synthase, and NADPH oxidase [2].
Neutrophils and Kupffer cells are the primary producers of free
radicals in the liver, whereas the major sites of ROS release in
hepatocytes are the cytochrome P450 system and mitochondria
[4]. In addition, iron may act synergistically with other free radical
sources to promote liver lipid peroxidation through the Fenton
reaction [5].
Nonalcoholic fatty liver disease (NAFLD), the most frequent
hepatic pathology [6], is characterized by the development of
oxidative stress and changes in redox balance [7]. The pathogen-
esis of NAFLD is multifactorial and includes lipid metabolism
alterations, mitochondrial dysfunction, inﬂammation, and oxida-
tive stress [8–12]; moreover, hepatic iron deposits in some cases
may contribute to NAFLD, even though their role is still contro-
versial [13]. Excessive accumulation of lipids is strongly associated
with insulin resistance [14], and it is widely accepted that NAFLD
represents the hepatic manifestation of a systemic impairment of
the insulin network [15]. However, it is still unclear whether
insulin resistance causes lipid storage in liver or whether the
increase in lipids itself or their metabolite intermediates may play
a causal role in the development of hepatic or systemic insulin
resistance [16]. The homeostasis of metabolic pathways is ﬁnely
modulated through a network of programs, which involves tran-
scription factors, kinases, and phosphatases, as well as nuclear
receptors (NRs). The result is a ﬁne balancing of the intermediary
metabolism to meet metabolic demands.
Free radicals play a role in the activation or inhibition of
signaling pathways that can modulate cellular lipid metabolism.
An example of how oxidative stress may dysregulate redox
signaling leading to hepatic steatosis is provided by alcoholic liver
disease (ALD) [17]. In fact, the oxidation of ethanol determines a
more reduced cellular state and activates the microsomal induc-
tion with consequent impaired utilization of oxygen and free
radical-induced toxicity [18], which in turn inhibit fatty acid
oxidation and promote lipogenesis through the modulation of
several NRs [19,20]. Even though NAFLD is histologically identical
to ALD, it is not associated with alcohol consumption and presents
a different natural history [21]. The dysregulation of redox biology
in NAFLD has already been extensively reviewed, particularly
pointing out its role in the progression of steatohepatitis and in
the involvement of adipokines and immune system [22–26].
The deﬁnition of redox-dependent molecular alterations respon-
sible for the development of steatosis provides new insights into
the role of ROS as controllers of liver lipid metabolism under
physiological and pathological conditions. Moreover, as several
ﬁndings suggest that increased ROS levels induce various signaling
pathways that may trigger insulin resistance in numerous settings
[27], a redox control may be implicated in the early development
of fatty liver.
Taking into account the pivotal role played by several NRs and
transcription factors in the development of NAFLD [28], this
review outlines the recent knowledge of the role played by free
radicals in the regulation of the transcriptional network that
modulates lipid metabolism in NAFLD, suggesting a redox-
centered pathogenic theory. Finally, updated evidence of the
impact of NAFLD on hepatic antioxidant defense and on the role
of antioxidant targeting therapy is also discussed.
Redox regulation of key enzyme activity in lipid metabolism
in NAFLD
The liver plays a central role in all the steps of lipid metabolism
(schematized in Fig. 1):
 lipogenesis by conversion of excess carbohydrates;
 fatty acid (FA) oxidation to produce energy;
 cholesterol and phospholipid metabolism.
Lipid metabolism is controlled by:
(1) the activity of key enzymes triggered by the binding of an
activator or inhibitor;
(2) post-translational modiﬁcations, which may shift the equili-
brium between an inactive and an active enzyme; and
(3) transcriptional regulation, which affects the level of expression
of key enzymes and is effective over a longer time scale.
Cellular redox state may affect the activity of several enzymes
involved in lipid metabolism, cause post-translational modiﬁca-
tions directly (glutathionylation, carbonylation), or by the mod-
ulation of phosphatases/kinases, act as second messengers or
induce conformational changes to NRs and/or act as NR ligands
[29]. The intracellular redox status is established by several redox
pairs, such as NADH/NADþ , NADPH/NADPþ , and reduced glu-
tathione/oxidized glutathione [30,31]. Thus, these ratios serve as
an index of the availability of reducing equivalents required for
lipogenesis. When an excess of reducing equivalents occurs in rat
liver mitochondria, β-oxidation may be partially suppressed
[32,33]. Some of the enzymes involved in lipid metabolism whose
activity is modulated by redox status are shown in Table 1.
NAFLD is a condition in which hepatocytes, which normally
hold only small amounts of storage lipid, contain supraphysiolo-
gical amounts of fat, caused by an imbalance between lipid uptake
and synthesis that exceeds oxidation and removal. Patients
affected by NAFLD show an increase in both uptake and synthesis
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[34,35], whereas experimental reduction of lipogenesis, consisting
in hepatic expression of malonyl-CoA decarboxylase (MCD) or
inhibition of acetyl-CoA carboxylase (ACC), reverses hepatic stea-
tosis [36,37]. Liver steatosis increases both lipid oxidation and the
tricarboxylic acid (TCA) cycle, whereas ketogenesis is not modiﬁed,
suggesting that hepatocytes try to counteract lipid excess by
enhancing oxidation [38]. β-Oxidation involves four individual
reactions that generate reducing equivalents (NADH or FADH2).
The energy produced is stored in the form of ATP by the oxidative
phosphorylation system coupled with the transfer of electrons
along the respiratory chain. The increased formation of reducing
equivalents by lipid oxidation causes an overﬂow of electrons
through the mitochondrial respiratory chain, resulting in higher
free radical generation (Fig. 2) [10,12]. Peroxisomal β-oxidation
generates hydrogen peroxide and is not coupled with phosphor-
ylating systems [39]. Microsomal oxidation also participates in the
adaptive response induced by lipid accumulation and in the
disorder of redox balance; in particular, cytochromes P4502E1
and P4504A are the major microsomal sources of oxidative stress
in NAFLD [40]. Thus, increased oxidation of fat by microsomes and
peroxisomes occurs in NAFLD and contributes to oxidative stress
(Fig. 2) [41–43].
Liver steatosis induces changes in the redox potential of
hepatocytes in both cytoplasm and mitochondria toward a more
reduced state, as demonstrated by alterations in the NADH/NADþ
ratio calculated for both cellular compartments from the β-
hydroxybutyrate dehydrogenase and lactate dehydrogenase reac-
tions [44], regulating some metabolic pathways occurring in these
compartments. The increased formation of reducing equivalents
could impair FA oxidation and the TCA cycle [45], but it could also
enhance the formation of glycerol-3-phosphate (G-3-P) and thus
lipogenesis [46]. In phosphoenolpyruvate carboxykinase-null mice,
a genetic model of liver steatosis, high mitochondrial reduction–
oxidation state and increased TCA cycle intermediate concentration,
as well as reduced oxygen consumption, occur. However, both TCA
and pyruvate cycles are dramatically reduced [47].
Saturation of lipids may also modify cellular redox status.
Among free FAs, monounsaturated fatty acids, such as oleic acids,
are less toxic than palmitate, a saturated acid, because the latter
increases the NADH/NADþ ratio and promotes uncoupling
between glycolysis and TCA cycle ﬂuxes, leading to increased
ROS production [48]. The hepatic accumulation of saturated FAs
can promote redox imbalance and the formation of reactive
oxygen intermediates, mainly inducing endoplasmic reticulum
(ER) stress and apoptosis [49]. In fact, polyunsaturated FA supple-
mentation signiﬁcantly improves redox balance and reduces
hepatic steatosis [50]. Because saturated FAs are the ﬁrst product
of de novo lipogenesis and exert lipotoxic effects by promoting
liver fat accumulation, stearoyl-CoA desaturase-1 (SCD1) is able to
prevent this accumulation and its toxic effects [51]. On the other
Fig. 1. Liver lipid metabolism. Hepatic lipogenesis includes de novo synthesis of fatty acids (FAs) from acetyl-CoA or malonyl-CoA and further processing to triglycerides
(TAGs) as energy stores. De novo synthesis of FA is started by acetyl-CoA carboxylase (ACC; the rate-limiting step), which converts acetyl-CoA into malonyl-CoA, and fatty acid
synthase (FAS), which catalyzes all of the reaction steps in the conversion of malonyl-CoA to saturated FA. The conversion of saturated to monounsaturated FAs is catalyzed
by the endoplasmic reticulum enzyme stearoyl-CoA desaturase-1 (SCD1). The formation of very long-chain FAs (VLCFAs) is mediated by elongases (Elovls), a family of
microsomal enzymes. TAG synthesis begins with the acylation of glycerol 3-phosphate (G-3-P) with a fatty acyl-CoA, producing lysophosphatidic acid, followed by further
acylation and dephosphorylation to yield diacylglycerol (DAG). The acylation of G-3-P represents the ﬁrst and committed step in glycerolipid biosynthesis; the reaction is
catalyzed by acyl-CoA:G-3-P acyltransferase (GPAT), located both in microsomes and in mitochondria. The ﬁnal step in TAG synthesis involves diacylglycerol acyltransferase
(DGAT), which converts DAG to TAG. The liver is also the major site of cholesterol synthesis, which depends on the cellular level of cholesterol induced by changes in the
amount and activity of 3-hydroxy-3-methylglutaryl CoA reductase (HMG-CoAR), which catalyzes the formation of mevalonate, the limiting step in cholesterol biosynthesis.
Cholesterol is synthesized in a 19-step process involving the activity of nine different enzymes. Cholesterol is converted to cholesterol esters primarily by the enzyme acyl-
CoA acyltransferase (ACAT), which is allosterically activated by cholesterol itself. Oxidation of FAs occurs within mitochondria and peroxisomes (β-oxidation), or endoplasmic
reticulum (ω-oxidation), and facilitates degradation of activated FAs to acetyl-CoA. Short- and medium-chain FAs freely enter mitochondria; in contrast, long-chain FAs
(LCFAs) are activated to acyl-CoA esters targeted to esteriﬁcation or to mitochondrial β-oxidation. Mitochondria are the gateway to the regulation of β-oxidation. Transfer
across the mitochondrial membrane is dependent on the activity of carnitine palmitoyl transferase 1 (CPT1), which may be inhibited by malonyl-CoA, produced in the ﬁrst
step of FA synthesis. Peroxisomes are preferentially involved in β-oxidation chain shortening of VLCFAs. Nevertheless, the peroxisomal pathway is quantitatively lesser:
FAs are chain-shortened only to shorter chain FAs followed by the transfer of these to mitochondria for full oxidation. VLCFAs are also metabolized by the cytochrome
P4504A ω-oxidation system to dicarboxylic acids. These acids are the preferred substrates for the peroxisomal β-oxidation pathway and are further shortened by
mitochondria. The ﬁnal product of FA oxidation, acetyl-CoA, is further processed through the tricarboxylic acid (TCA) cycle or, in the case of FA abundance, is converted into
ketone bodies, a process directly controlled by mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase (HMG-CoAS).
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hand, SCD1 is strongly downregulated in a dietary model of NAFLD,
resulting in enhanced delivery of FAs to mitochondria and oxidation
that in turn increases mitochondrial ROS production and release
[52], and its causes are the object of active investigation.
The role of cholesterol accumulation in hepatic steatosis is an
emerging topic, because it can further contribute to the alteration
of cellular redox status. Several studies reported that free choles-
terol (but not cholesteryl esters) accumulates in human NAFLD and
strongly associates with the progression and the severity of liver
damage [53,54]. This accumulation arises from high cholesterol
synthesis rather than elevated ﬂux from intestinal absorption
[51,55]. The accumulation of free cholesterol in liver mitochondria
leads to speciﬁc mitochondrial glutathione depletion, sensitizes
the hepatocytes to tumor necrosis factor and Fas-mediated apop-
tosis and induces steatohepatitis [56]. Very interestingly the
catalytic activity of 3-hydroxy-3-methylglutaryl-CoA reductase
(HMG-CoAR), the rate-limiting step in cholesterol synthesis, may
be regulated by its thiol redox status [57]. Accordingly, cholesterol
accumulation depletes mitochondrial glutathione and this redox
change milieu may inhibit hepatic HMG-CoAR activity, as sug-
gested in [58].
Redox-dependent post-translational protein modiﬁcations
in NAFLD
Redox-dependent post-translational protein modiﬁcations arise
either from direct oxidation of amino acid residues or through the
formation of reactive intermediates by the oxidation of other cellular
components. Furthermore, a signiﬁcant portion of ROS-induced post-
translational modiﬁcations result in the addition of reactive carbonyl
functional groups on proteins, generically termed “protein carbony-
lation,”with the most reactive and common of these carbonyl groups
being in the form of aldehydes [59]. Protein carbonylation can result
directly from a variety of reactions or from an indirect mechanism
involving the hydroxyl radical-mediated oxidation of lipids. Recent
studies suggested that protein carbonylation formed from lipid-
derived aldehydes is more prevalent than that formed via direct
amino acid side-chain oxidation [60]. The most reactive aldehydes
generated from polyunsaturated fatty acid oxidation are α,β-unsatu-
rated aldehydes, including 4-hydroxynonenal (4-HNE) [61]. Posttran-
slational protein oxidation frequently leads to enzyme inactivation or
targeted degradation, but it can also lead to a functional gain for
certain metabolic signaling pathways [59].
Table 1
Enzymes involved in hepatic lipid metabolism regulated by redox status.
Pathway Enzyme Redox regulation
Fatty acid synthesis Fatty acid synthase Inhibited by a reduction in NADPH/NADPþ or by a reduction in GSH/GSSG
Fatty acid synthesis Glycerol-3-phosphate acyltransferase Activated by an increase in NADH/NADþ
Cholesterol synthesis 3-Hydroxy-3-methylglutaryl-CoA reductase Inhibited by a reduction in GSH/GSSG; activated by an increase in NADH/NADþ
Fatty acid oxidation Acyl-CoA dehydrogenase Inhibited by an increase in NADH/NADþ
Fatty acid oxidation β-Hydroxyacyl-CoA dehydrogenase Inhibited by an increase in NADH/NADþ
Tricarboxylic acid cycle Citrate synthase Inhibited by an increase in NADH/NADþ
Tricarboxylic acid cycle Isocitrate dehydrogenase Inhibited by an increase in NADH/NADþ
Tricarboxylic acid cycle α-Ketoglutarate dehydrogenase Inhibited by an increase in NADH/NADþ
Fig. 2. Sources of free radicals in fatty liver during lipid metabolism. Liver steatosis increases lipid oxidation and activity of the TCA cycle, whereas ketogenesis is not
modiﬁed. The increased formation of reducing equivalents by lipid oxidation causes an overﬂow of electrons through the mitochondrial respiratory chain (OXPHOS),
resulting in higher free radical generation. Excess of long-chain fatty acids (LCFAs) enhances peroxisomal β-oxidation, with consequent generation of hydrogen peroxide.
Accumulation of very long chain fatty acids (VLCFAs) induces microsomal oxidation with consequent production of free radicals particularly by cytochromes P4502E1 and
P4504A. Other abbreviations used: ACC, acetyl-CoA carboxylase; MCD, malonyl-CoA desaturase; FAS, fatty acid synthase; CPT1, carnitine palmitoyl transferase 1; SCD1,
stearoyl-CoA desaturase 1; Elovl, elongase; HMG-CoAR, 3-hydroxy-3-methyl-glutaryl-CoA reductase; GPAT, acyl-CoA:G-3-P acyltransferase; ACAT, acyl-CoA acyltransferase;
DGAT, diacylglycerol acyltransferase; DAG, diacylglycerol; TAG, triacylglycerol.
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Accumulation of oxidatively modiﬁed proteins and lipid per-
oxides acids was described in NAFLD and is assumed to induce
liver disease progression [45,62,63]. Protein glutathionylation also
increases in livers with nonalcoholic steatohepatitis (NASH) [64].
However, selectively oxidized target proteins are poorly character-
ized and merit further investigation.
Some proteins involved in FA metabolism may be post-transla-
tionally modiﬁed. In particular, speciﬁc adducts between 4-HNE
and CPT-1 were observed in a model of NAFLD, with consequent
decreased expression and activity of the protein [65]. Similarly,
adducts between 4-HNE and the uncoupling protein 2 (UCP-2)
were also reported both in rats and in patients with NASH, but
the 4-HNE–UCP-2 adduct was associated with increased uncou-
pling [12].
Redox balance and insulin control of lipid metabolism in
NAFLD
Postprandial insulin secretion induces hepatic glucose uptake
by stimulating the translocation of glucose transporter 2 from
intracellular vesicles to plasma membrane; moreover, high post-
prandial insulin inhibits gluconeogenesis and stimulates glycogen
synthesis [66]. When not redirected to glycogen pools, excess
glucose is used in de novo lipogenesis. Insulin triggers lipogenesis,
suppresses peripheral lipolysis by inhibiting hormone-sensitive
lipase, and indirectly antagonizes mitochondrial FA oxidation by
increasing malonyl-CoA concentration [67,68]. Millimolar concen-
trations of H2O2 may activate insulin signaling and/or induce
metabolic actions of insulin by the tyrosine phosphorylation of
the insulin receptor β-chain [69,70]. The insulin receptor kinase
activity itself may be oxidatively regulated, because ATP binding,
required for the receptor autophosphorylation process, is modu-
lated by H2O2 [71]. However, the main underlying mechanism for
the insulinomimetic effect of H2O2 is the inhibition of the catalytic
activity of various protein and lipid phosphatases, which act as
negative regulators and off-mechanisms of insulin signaling [72–75].
Free radicals may strengthen the insulin signaling by acting as second
messengers in adipocytes and muscle cells [76,77], but evidence for
this in hepatocytes is still lacking. The redox environment may also
regulate the insulin-degrading enzyme and thus insulin half-life and
action [78].
Hepatic lipid accumulation is strongly dependent on insulin
sensitivity; however, the causal relationship has not yet been
completely deﬁned, because it is not clear whether hepatic
steatosis increases insulin resistance or, conversely, NAFLD is the
ﬁnal effect of insulin resistance. It is conceivable that a common
underlying molecular pathophysiology may account for the two
effects [79]. Very interestingly, it has been demonstrated that
oxidation of palmitate but not oleate induces insulin resistance
through excess mitochondrial electron ﬂux and consequent ROS
production by inhibiting signal transduction through c-Jun NH2-
terminal kinase (JNK) [80]. Moreover, it was observed that CPT-1
reduction and superoxide dismutase activity, together with
impaired FA oxidation and glutathione oxidation, occur before
insulin resistance [81].
Different lipid classes may also have different effects on insulin
sensitivity, according to their oxidative properties. Dietary supple-
mentation of n-3 long-chain-polyunsaturated FAs reduced hepatic
lipid content, with concurrent antioxidant and anti-inﬂammatory
responses and improvement of insulin sensitivity [50,82]. Hepatic
cholesterol accumulation per se does not induce insulin resistance
but increases hepatic steatosis [83,84]. Several experimental
models clariﬁed that both high fat and cholesterol are needed to
produce hepatic steatosis and insulin resistance [83,85]. Because
free cholesterol accumulation in mitochondria leads to glutathione
depletion and lipid peroxidation [56], and because cholesterol
accumulation also leads to oxysterol formation [86], it is concei-
vable that cholesterol accumulation impairs redox status and
induces insulin-dependent signaling. Taken together, this evidence
suggests that lipids accumulating in liver steatosis function as
bioactive substances that interfere with the ability of hepatocytes
to respond to changes in insulin level. However, to date, studies
failed to identify a speciﬁc lipid necessary and sufﬁcient to
determine hepatic insulin resistance [79]. Thus, excess bioactive
lipids do not act alone as contributing factors but rather as part of
a signal in which radical molecules generate reactive intermedi-
ates and exert signaling functions.
Redox control of lipid metabolism by nuclear receptors in
normal liver and NAFLD
Control of lipid metabolism is mediated by a network of NRs
that respond to several ligands to regulate the expression of
enzymes that participate in hepatic lipogenesis or lipoxidation in
a thin form of coordination [87]. Several endogenous and exogen-
ous lipids such as cholesterol or FAs act as physiological NR
ligands, and NRs may be viewed as “lipostats” because their
activation frequently promotes metabolism/catabolism of their
respective ligands and/or provides a negative feedback for self-
termination of synthesis [88]. Very interestingly, free radical-
derived molecules may act as NR ligands or alter their DNA
binding or nuclear import [29]. Among the various NRs taking
part in the physiological regulation of lipid metabolism and
pathological modulation by free radicals during hepatic steatosis
(Table 2), the role of peroxisome proliferator-activated receptors α/
γ/δ (PPARα/γ/δ), PPARγ coactivators 1α and 1β (PGC-1α/β), sterol-
regulatory element binding proteins (SREBPs), AMP-activated
protein kinase (AMPK), liver-X-receptors (LXRs), and farnesoid-X-
receptor (FXR) are speciﬁcally addressed here (Fig. 3).
PPAR family
PPARs are activated by peroxisome proliferators—a miscella-
neous group of rodent hepatocarcinogens that include hypolipi-
demic drugs, plasticizers, and herbicides; there are four PPAR
isoforms within vertebrates termed α, γ, and β/δ [89].
PPARα induces genes involved in mitochondrial as well as
peroxisomal and microsomal FA oxidation [90–92]. Both polyun-
saturated FAs eicosapentaenoic acid (C20:5n-3) and docosahexae-
noic acid (C22:6n-3), and long chain-FA-CoA, bind and activate
PPARα and increase FA oxidation, gluconeogenesis, and ketogen-
esis [93]. PPARα binds to the PPAR response element as a
heterodimer with the retinoid-X-receptor (RXR) [94]. The expres-
sion of PPARα, by activation of acyl-CoA oxidase (ACOX)—a key
enzyme initiating FA β-oxidation—was signiﬁcantly reduced in a
rodent model of NAFLD; on the other hand, PPARα agonists
improved steatosis [95,96]. Mice deﬁcient in PPARα and those
deﬁcient in both PPARα and ACOX exhibit severe hepatic steatosis
when subjected to fasting, indicating that a defect in PPARα-
inducible FA oxidation accounts for severe FA overload in liver,
in contrast to the wild-type mice, which respond by enhancing
FA oxidation [92,97,98]. The expression of PPARα is also reduced
in patients with NAFLD, and PPARα gene polymorphism distribu-
tion may inﬂuence the pathogenesis of human hepatic steatosis
[99,100]. Human liver cells exposed to H2O2 show a downregula-
tion of PPARα expression, as well as its target genes ACOX and
CPT-1, which control FA oxidation, indicating that the alteration of
lipid homeostasis might be dependent on a free radical-mediated
signaling (Fig. 4) [101]. On the other hand, PPARα expression is
associated with that of Cu2þ , Zn2þ-superoxide dismutase (SOD)
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expression in liver [102], and a peroxisome proliferator-response
element has been identiﬁed in the catalase (CAT) gene [103],
suggesting that PPARs may also modulate antioxidant response
(Fig. 4). PPARα also protects hepatocytes from potential oxidative
damage developed during fasting, because fasted PPARα-null mice
exhibit marked hepatic steatosis associated with elevated levels of
lipid peroxidation, nitric oxide synthase activity, and hydrogen
peroxide accumulation, as well as reduced levels of total glu-
tathione (GSH), mitochondrial GSH, and activities of major anti-
oxidant enzymes [104].
PPARγ plays a crucial role in adipogenesis and insulin sensiti-
zation; the main role of PPARγ in the liver is related to the
regulation of glucose and lipid metabolism; however, its hepatic
expression level is 9–12% that of adipose tissue in humans
[105,106]. High expression levels are associated with induction
of PPARγ-responsive genes related to lipid metabolism. These
include: (1) lipoprotein lipase; (2) proteins involved in FA uptake,
binding, and transport, such as FA translocase (FAT/CD36), FA
transport proteins 2 and 5, and FA-binding proteins 1 and 5; and
(3) LXR favoring both PPARγ and FAT/CD36 expression [107,108].
Assessment of hepatic PPARγ expression in humans with hepatic
steatosis has produced conﬂicting results, showing comparable,
decreased, or increased levels [99,109,110]. A comparison between
these studies suggests that the expression of PPARγ is enhanced in
association with increased body mass index and insulin resistance,
which may represent additional mechanisms upregulating genes
that encode lipogenic proteins leading to hepatic steatosis [110].
The use of PPARγ ligands such rosiglitazone or pioglitazone for
treatment of NAFLD patients has demonstrated an improvement in
glucose and lipid metabolism, as well as hepatic inﬂammation and
fat storage [111–113]. However, the treatment response of PPARγ
ligands is extremely variable and difﬁcult to predict, because of
single-nucleotide polymorphisms in several target genes [114]. The
mechanisms underlying the responsiveness or nonresponsiveness
Table 2
Modiﬁcations in the expression of nuclear receptors that modulate hepatic lipid metabolism during NAFLD.
Nuclear receptor Target proteins Modiﬁcation in NAFLD
Peroxisome proliferator-activated receptor α Acyl-CoA oxidase Reduced expression in humans [99] and animal models [95]
Peroxisome proliferator-activated receptor γ Increased [99,110] or decreased [109] expression in humans
Peroxisome proliferator-activated receptor γ coactivator α Mitochondrial transcription factor A Reduced expression in humans [137]
Sterol-regulatory element-binding protein 1c Acetyl-CoA carboxylase, fatty acid synthase Increased expression in humans [99,150]
Sterol-regulatory element-binding protein 2 Hydroxymethyl glutaryl-CoA reductase Increased expression in humans [154] and rodents [153]
AMP-activated protein kinase No modiﬁcations in humans [150,173]
Liver-X-receptor Sterol-regulatory element-binding protein 1c Increased expression in humans [173]
Farnesoid-X-receptor Decreased expression in humans [207]
Fig. 3. Nuclear receptor interplay involved in the regulation of lipid metabolism. Fatty acid oxidation is favored by peroxisome proliferator-activated receptors α and β/δ
(PPARα and β/δ), respectively activated by polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), long-chain fatty acid-CoA (LCFA-CoA),
ﬁbrates, and the synthetic ligand GW501516. In contrast, PPARγ, activated by thiazolidinediones, triggers fatty acid uptake. PPARγ coactivator 1α (PGC-1α) orchestrates a
complex program of metabolic changes that occur during the transition of a fed to a fasted liver, including mitochondriogenesis, fatty acid oxidation, and bile acid
homeostasis; PGC-1β is induced by dietary intake of fats and leads to hyperlipidemia by activating hepatic lipogenesis. Sterol-regulatory element-binding protein 1c (SREBP-
1c), activated by insulin receptor substrate proteins (IRSs), controls hepatic de novo lipogenesis by regulating the expression of key genes involved in fatty acid synthesis and
glucose metabolism, whereas SREBP-2 predominantly regulates cholesterol synthesis. AMP-activated protein kinase (AMPK) negatively regulates PPARα and PPARγ, as well
as SREBP-1c and -2, but activates PGC-1α to turn on ATP-producing processes, such as fatty acid oxidation, and turn off ATP-consuming processes such as fatty acid synthesis.
Liver-X-receptors (LXRs), activated by physiological concentrations of sterols, are crucial for the control of lipid homeostasis by enhancing gene transcription involved in
regulation of fatty acid and cholesterol metabolism through SREBP induction. Activation of farnesoid-X-receptor (FXR) by endogenous bile acids inhibits bile acid synthesis
from cholesterol and also protects against the toxic accumulation of bile acids through increased conjugation in the liver and secretion into bile canaliculi.
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of this treatment are largely unknown [112,113]. Very interestingly,
it has been demonstrated that during adipocyte differentiation
there is an mTORC1-dependent increase in mitochondrial metabo-
lism and biogenesis with consequent increased production of
mitochondrial Complex III ROS resulting in the induction of PPARγ
transcriptional machinery required to initiate adipocyte differentia-
tion [115]. However, exposure of endothelial cells to H2O2 leads to
inhibition of PPARγ gene expression, but does not affect protein
level or activity (Fig. 4); these effects are preserved by catalase and
are not reproduced by other oxidant molecules [116]. The lipid
peroxidation product 4-HNE is effective in the modulation of PPARγ
activity through the pathways modulating leukemic cell growth and
differentiation [117]. However, there is no evidence relating to the
free radical biology of PPARγ in hepatocytes, and this ﬁeld merits
further investigation.
PPARβ/δ is expressed in most metabolically active tissues, but
is the only subtype that is not a target of current drugs. Early data
have suggested that adipose differentiation-related protein, a lipid
droplet coating protein, acts as a lipid sensor, being a PPARβ/δ
target gene [118]. Further studies revealed that PPARβ/δ controls
an array of metabolic genes involved in glucose homeostasis and
fatty acid synthesis/storage, mobilization, and catabolism in a
tissue-speciﬁc manner [119–121]. Several synthetic ligands have
also been developed, to improve symptoms of metabolic disorders
[122,123]. Experimental data support that the combined hepatic
and muscular effects of PPARβ/δ constitute a “fatty acid futile
cycle,” resulting in improved glucose and lipid metabolism [124].
The effect of the selective PPARβ/δ ligand GW501516 in a mouse
model of hepatic steatosis consisted in reduced hepatic TAG and in
the number of fatty liver droplets [125]. A study using adenovirus-
mediated liver-restricted PPARβ/δ activation demonstrated the con-
trol of hepatic energy substrate homeostasis by coordinated regula-
tion of glucose and fatty acid metabolism, through transcriptional
mechanisms partly mediated by its coactivator, PGC-1β, and by
AMPK [126].
The extent of liver toxicity by treatment with the xenobiotics
azoxymethane, arsenic, or carbon tetrachloride in PPARβ/δ-null
mice is more severe than in wild-type mice, suggesting that the
presence of this receptor is important in ameliorating the effects of
hepatotoxicants [127]. One possible explanation for the increased
susceptibility of PPARβ/δ / mice to hepatotoxicity is that oxida-
tive damage increases the production of an endogenous ligand for
PPARβ/δ, which would in turn stimulate lipid metabolism and
degradation of lipid peroxidation intermediates. Accordingly, it
was reported that 4-HNE is able to activate PPARβ/δ receptor in
transient transfection reporter assays [128]. Moreover, the activa-
tion of PPARβ/δ by 4-HNE increased the expression of alcohol
dehydrogenase and glutathione S-transferases, providing evidence
of a feedback regulation of gene expression that reduces liver
toxicity (Fig. 4) and reveals a cross talk between PPARβ/δ and
energy homeostasis in cellular events during inﬂammation [128].
PGC-1 family
Transcriptional coactivators are recruited to liganded NRs and
function in part by stimulating gene expression, covalently mod-
ifying histones, and mediating interactions between transcription
factors [129]. PGC-1 family members are multifunctional tran-
scriptional coregulators that act as “molecular switches” in many
metabolic pathways. PGC-1α and PGC-1β regulate adaptive ther-
mogenesis, mitochondrial biogenesis, and glucose/FA metabolism
by interacting with various transcription factors in a tissue-speciﬁc
manner [130].
PGC-1α is abundantly expressed in tissues with high energy
demand and strongly stimulates the program of nuclear- and
mitochondrial-encoded mitochondrial genes as well as organelle
Fig. 4. Interplay between nuclear receptors and free radicals during fatty liver progression. Hydrogen peroxide may downregulate peroxisome proliferator-activated
receptors α and γ, with consequent repression of acyl-CoA oxidase (ACOX) and carnitine palmitoyl transferase-1 (CPT-1) and a possible induction of Cu2þ , Zn2þ-superoxide
dismutase (SOD) and catalase (CAT). On the other hand, hydrogen peroxide activates sterol-regulatory element-binding protein 1c (SREBP-1c) and lipogenesis through fatty
acid synthase (FAS) induction, as well as AMP-activated protein kinase (AMPK). The latter nuclear receptor can also be activated by reactive oxygen species speciﬁcally
produced by mitochondria (mROS), probably to preserve the redox environment. Mitochondrial ROS may also play a key role in the control of PPARγ coactivator 1α (PGC-1α)
expression, with improvement in insulin sensitivity as ﬁnal effect. The activation of PPARβ/δ by the lipid peroxidation product 4-hydroxynonenal (4-HNE) upregulates
alcohol dehydrogenase (ADH) and glutathione S-transferases (GSTs), suggesting a feedback mechanism pointing at a reduction of liver toxicity. The oxysterol 22-
hydroxycholesterol (22-HC) activates farnesoid-X-receptor (FXR), inducing the expression of the bile salt export pump (BSEP), which mediates the secretion of bile acids
from the liver.
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biogenesis through its coactivation of nuclear respiratory factors
1 and 2 (NRF1 and NRF2) and the estrogen-related receptor α
[131–133]. The induction of NRF1 and NRF2 leads in turn to the
increased expression of mitochondrial transcription factor A
(mtTFA) as well as other mitochondrial subunits of the electron
transport chain complex such as ATP synthase, cytochrome c, and
cytochrome oxidase [131,134]. mtTFA translocates to the mito-
chondrial matrix, where it stimulates mitochondrial DNA replica-
tion and mitochondrial gene expression [135]. PGC-1α
orchestrates a complex program of metabolic changes that occur
during the transition of a fed to a fasted liver, including gluconeo-
genesis, FA oxidation, ketogenesis, and bile acid homeostasis.
These effects are achieved by coactivating key hepatic transcrip-
tion factors, such as hepatic nuclear factor 4α, PPARα, forkhead
box class O1 (FOXO1), FXR, and LXRs [136]. Transcriptional activity
of PGC-1α is tightly related to peripheral insulin sensitivity in
NAFLD patients through epigenetic modiﬁcations [137].
There is signiﬁcant evidence as regards the role of PGC-1α as a
redox sensor. When primary vascular endothelial cells are treated
with NO donors, a short-term downregulation of PGC-1α
mediated by protein kinase G occurs after short-term treatment,
whereas a long-term treatment upregulates PGC-1α, suggesting
that the primary effect of NO is the suppression of PGC-1α
expression, and the induction phase must be a secondary process
[138]. These changes lead to variations in the expression of
antioxidant genes, suggesting that NO can elicit both pro-oxidant
and antioxidant effects through the regulation of PGC-1α expres-
sion, and the analysis of several tissues from endothelial NO
synthase-deﬁcient mice suggests that NO regulation of the mito-
chondrial detoxiﬁcation system through PGC-1α takes place
in vivo and is not conﬁned to the vascular endothelium only
[138]. ROS generation and the resultant alteration of intracellular
redox status activate the PGC-1α signaling pathway through p38
mitogen-activated protein kinase (MAPK) and cAMP-responsive
element-binding protein (CREB) phosphorylation in skeletal mus-
cle contraction [139]. Moreover, the use of allopurinol (an inhibitor
of xanthine oxidase) before exercise severely attenuated exercise
activation of the PGC-1α signaling pathway, thus providing strong
evidence to suggest that mitochondrial biogenesis in skeletal
muscle is controlled at least in part by nonmitochondrial ROS
[139]. Very interestingly, ROS induced the activation of CREB and
PGC-1α in a line of human liver cells (Fig. 4), and the over-
expression of hepatic SOD1 in genetically diabetic mice improved
insulin sensitivity by downregulating this signaling and attenuat-
ing FOXO1 [140]. These ﬁndings suggest that mitochondria ROS
may play a key role in the control of PGC-1α expression, with
improvement in insulin sensitivity, pointing out this signaling
pathway as a potentially suitable therapeutic target for the
prevention or treatment of insulin resistance [140].
PGC-1β expression is increased in response to dietary intake of
fats and leads to hyperlipidemia by activating hepatic lipogenesis
and very low density lipoprotein secretion [136]. Several factors
are involved in mediating the effects of PGC-1β on lipid metabo-
lism, including SREBPs, LXRs, and FOXA2 [136,141].
SREBP family
De novo lipogenesis is modulated by multiple mechanisms,
including increased expression of lipogenic enzymes under the
control of several speciﬁc transcription factors; this is particularly
true for members of the SREBP family. SREBP molecules are
transcribed and translated into inactive precursors embedded in
the membrane of the endoplasmic reticulum; the release of the
transcriptionally active domain by a sequential two-step proteo-
lytic machinery is controlled by complex metabolic regulation. The
mature forms of SREBPs translocate into the nucleus and facilitate
the expression of target genes [142,143]. SREBP-1c controls hepa-
tic de novo lipogenesis primarily by regulating the expression of
key genes involved in FA homeostasis and glucose metabolism,
whereas SREBP-2 predominantly regulates cholesterol synthesis
[16,144,145]. Insulin stimulates lipogenesis by hepatic expression
of SREBP-1c through activation of insulin receptor substrate (IRS)
proteins [146,147]. In addition, IRS also suppresses FA oxidation
through the inhibition of FOXA2 [148].
In NAFLD patients, IRS-1 expression is enhanced and positively
correlated with SREBP-1c expression, leading to the increased
synthesis of FA in hepatocytes; moreover, negative feedback via
AMPK does not occur and the activation of FOXA upregulates FA
oxidation [99,149,150]. Liver-speciﬁc expression of transcription-
ally active SREBP-1c is associated with hepatic steatosis [151]. The
prevention of SREBP-1a phosphorylation by MAPKs protects
against liver steatosis development in mice [152]. Hepatic choles-
terol accumulation is sustained by SREBP-2 activation in obese and
diabetic mice [153]. SREBP-1c, together with its target gene FAS, is
not induced in NAFLD patients; in contrast, an increase in SREBP-2
and its target genes HMG-CoA reductase and the mitochondrial
cholesterol-transporting polypeptide steroidogenic acute regula-
tory protein was observed [54]. The recent demonstration of an
enhanced SREBP-2 maturation in nonobese patients with liver
steatosis associated with increased synthesis of cholesterol
increases the role played by abnormal cholesterol metabolism in
NAFLD pathogenesis [154].
In HepG2 cells hypoxia and H2O2 induced activation of Akt and
hypoxia inducible factor 1, together with upregulation of SREBP-1,
with a ﬁnal increase of FAS (Fig. 4). The authors suggested that the
increased activity of FAS enhances lipogenesis, with more NADPH
consumed, and that this rebalances the redox state, which permits
the cells to compensate for the shortfall in oxygen [155]. Indeed,
H2O2 directly induces SREBP-1c transcriptional activity in the
same cells, leading to lipid accumulation [156]. Because SREBP-
1c activation is under the regulation of insulin signaling, H2O2
activates this pathway via the insulin-signaling cascade; alterna-
tively, endoplasmic reticulum stress evoked by the accumulation
of misfolding proteins under the stimulation of ROS and other
stressors may activate JNK [157] and then SREBPs [156,158,159]. It
is worth noting that some natural antioxidant compounds reduce
fatty liver by downregulation of SREBP-1c and consequently FAS,
ACC, and SCD1 [160]. Because the antioxidants tested are not able
to bind SREBP-1c directly, it is conceivable that they act as
modulators of the cellular redox environment.
AMP-activated protein kinase
AMPK is a heterotrimeric kinase that contains two regulatory
subunits, β and γ, and one of the isoforms of the α-catalytic subunit,
α1 or α2. AMP, the classical activator of AMPK, binds the γ-subunit
and induces a conformational change allowing phosphorylation at
the Thr172 residue of the α-subunit or reducing the ability of
phosphatases to remove the phosphate [161]. AMPK is activated
by hypoxia, ischemia, hyperosmolality, ROS, hypoglycemia, and
stimulation of signaling pathways [162–164]. Regardless of the
stimulus, once activated, AMPK turns on ATP-producing processes,
such as FA oxidation and glycolysis, and turns off ATP-consuming
processes such as FA synthesis [165]. When intracellular FA levels
increase, AMPK inhibits hepatic FA and cholesterol synthesis by
SREBP-1c downregulation [166,167]. The SREBP-1c gene is induced
by insulin through increased activity of LXRs [168]; on the other
hand, AMPK—activated by glucagon [169]—directly inhibits ligand-
induced LXR activity [170]. Moreover, AMPK activation leads to
PPARα and PPARγ inhibition and also to phosphorylation and
consequent activation of PGC-1α [171,172].
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AMPK levels in NAFLD patients are similar to those in healthy
people [150,173]. Because of its favorable global metabolic effects,
AMPK is considered a possible therapeutic target in the prevention
and treatment of hepatic steatosis [166]. Sauchinone—an AMPK-
activating ligand—inhibits LXRα-mediated SREBP-1c induction and
SREBP-1c-dependent hepatic steatosis, thereby protecting hepato-
cytes from oxidative stress induced by fat accumulation in an
animal model [174]. The activation of AMPK by synthetic poly-
phenols protects against liver steatosis by repression of lipogenesis
through direct inhibition of SREBP-1c and SREBP-2 [175].
AMPK is transiently and concentration-dependently activated
by H2O2 in NIH-3T3 cells (Fig. 4), and this activation is signiﬁcantly
blocked by the pretreatment of 0.5% dimethyl sulfoxide, a potent
hydroxyl radical scavenger, indicating that the AMPK cascade is
highly sensitive to oxidative stress [176]. In vascular endothelial
cells mitochondria generate ROS for AMPK activation by a
mechanism independent of AMP/ATP concentration, indicating a
role in cellular defense because it leads to cardioprotection and the
inactivation of caspase-3 [177]. Indeed, it was shown that mito-
chondrial ROS production (and not an increase in the AMP/ATP
ratio) is required for hypoxic AMPK activation; in particular, ROS
generated by Complex III of mitochondria are the stimulus for the
activation of AMPK signaling, as demonstrated by a failure of
hypoxia to activate AMPK in cells that are deﬁcient in cytochrome
b, a subunit of the mitochondrial Complex III [178]. Exposure of
recombinant AMPKαβγ complex or HEK 293 cells to H2O2 is
associated with increased kinase activity and also results in
S-glutathionylation of the AMPKα and AMPKβ subunits [44].
Moreover, activation and S-glutathionylation of the AMPKα sub-
unit are present in the lungs of acatalasemic mice or mice treated
with the catalase inhibitor aminotriazole, i.e., conditions under
which intracellular H2O2 steady-state levels are increased [44].
The activation of AMPK by oxidative stress could be justiﬁed by
its ability to activate reducing metabolic pathways in tumor cells
to preserve the redox environment; in fact, the inhibition of ACC
by AMPK maintains NADPH levels by decreasing NADPH con-
sumption in FA synthesis and increasing NADPH generation by FA
oxidation [179]. Though the effects of a redox-dependent regula-
tion of AMPK in NAFLD still need to be clariﬁed, nevertheless
when palmitate-charged HepG2 cells are treated with the ﬂavo-
noid luteolin, the phosphorylation of AMPK is enhanced, together
with upregulation of CPT-1 and ACC and downregulation of
SREBP-1c and FAS, with a ﬁnal lipid-lowering effect [180].
Liver-X-receptor family and farnesoid-X-receptor
LXRs α (NR1H3) and β (NR1H2) are critical for the control of
lipid homeostasis; they respond to physiological concentrations of
sterols [181]. Upon ligand-induced activation, both isoforms con-
stitute compulsory heterodimers with the RXR and regulate gene
expression through binding to LXR-response elements in the
promoter regions of the target genes [182]. In the absence of
ligands, LXR recruits complexes of corepressors that are exchanged
with coactivators on receptor activation [183].
LXRs are crucial for the control of lipid homeostasis and not
only for enhancing gene transcription involved in regulation of
cholesterol metabolism [184]. As well as inducing SREBP-1c,
LXRα also induces carbohydrate-response element-binding pro-
tein A, a glucose-sensitive transcription factor that promotes the
hepatic conversion of excess carbohydrate to lipid, activating
lipogenic gene expression [185], and directly enhances the expres-
sion of lipogenic genes through LXRα-response elements in their
promoters [186]. In NAFLD, LXR expression is four times higher
than in healthy subjects and is signiﬁcantly correlated to SREBP-1c
[173]. Elevated cholesterol production may induce an increase in
oxysterol levels, LXR and SREBP-1c activation, and fatty acid
synthesis [187].
Oxysterols are mostly oxygenated forms of cholesterol
[188,189], formed enzymatically in the ﬁrst steps of cholesterol
metabolism or directly from cholesterol by ROS, and act as active
molecules and ligands for LXR in the regulation of lipid metabo-
lism, but also in several cell signaling pathways [190,191]. Circu-
lating levels of oxysterols are increased in NAFLD patients,
suggesting an important role for these ligands in the pathogenesis
of this disease [86]. LXR-linking oxysterols are intermediate com-
pounds of cholesterol synthesis (24,25-hepoxycholesterol) or steroid
hormone synthesis (22-hydroxycholesterol and 20-hydroxycholes-
terol) or products of cholesterol hydroxylase (24-hydroxycholesterol,
24-HC; 25-hydroxycholesterol, 25-HC; 27-hydroxycholesterol, 27-
HC) [192]. Among them, 24-HC and 27-HC are the main circulating
oxysterols in humans. 27-HC is the product of hepatic mitochondrial
25-hydroxylase, involved in the mitochondrial transport of choles-
terol [193].
Because oxysterols are natural ligands of LXR it has been
suggested that LXR may act as a cellular sensor of oxidative stress.
Some evidence suggests that redox status may modulate the
activation of LXRs. The expression of LXRs and PPARs is impaired
by a strong peroxidation induced by iron ascorbate in macro-
phages, and this leads to downregulation of ATP-binding cassette
A1, a crucial unidirectional cholesterol exporter, thus impairing
cholesterol efﬂux; this effect is reversed by the use of powerful
antioxidants, such as Trolox and butylated hydroxytoluene, sug-
gesting that the redox environment is crucial in the regulation of
LXR-mediated cholesterol handling [194]. Vitamin C supplementa-
tion selectively activates LXRα-dependent signaling pathways in
mononucleate cells, which in turn downregulates its effector gene
matrix metalloproteinase-9, thus reducing the atherogenic process
[195]. It is also interesting to note that deletion of the nuclear
factor (erythroid-derived 2)-like 2 (NFE2L2), which activates the
antioxidative cellular response, leads to severe liver steatosis in
animals fed a high-fat and atherogenic diet by downregulating
LXRs and the other NRs that regulate fatty acid metabolism in
hepatocytes [196]. Indeed, a deﬁciency in NFE2L2 enhances the
ability of the LXRα agonist to promote hepatic steatosis, as
mediated by lipogenic gene induction, whereas NFE2L2 over-
expression in hepatocytes represses gene transactivation by LXR-
binding site activation [197]. Thus, given the role of NFE2L2
biology in the modulation of cellular redox status [198], it is
conceivable that the changes in the redox environment that occur
in NAFLD could contribute to the direct activation of LXRs.
FXR regulates, directly or through the orphan nuclear receptor
small heterodimer partner, a wide variety of target genes critically
involved in the control of bile acid, lipid, and glucose homeostasis
and in the regulation of immune responses [199]. Like LXRs, FXR
may also form a heterodimer with RXR to modulate the expression
of target genes [200]. Activation of FXR inhibits bile acid synthesis
from cholesterol and also protects against the toxic accumulation
of bile acids through increased conjugation in the liver and
secretion into bile canaliculi [199]. Thus, FXR signaling is function-
ally related to LXR signaling [201]. FXR is a biosensor for endo-
genous bile acids: chenodeoxycholic acid (a primary bile acid) is
the most potent natural FXR agonist, and lithocholic acid and
deoxycholic acid (secondary bile acids) also activate FXR, but to a
lesser extent [202,203].
FXR-deﬁcient mice display elevated serum levels of TAG and
cholesterol, demonstrating the crucial role of FXR in lipid meta-
bolism [204]. In human cells, FXR activation induces expression of
PPARα and its target genes [205]. Moreover, FXR is induced by
PGC-1α both directly and indirectly via PPARγ [206]. Thus, FXR
reduces lipogenesis and promotes increased uptake, catabolism,
and oxidation of TAGs and FAs. In NAFLD patients, the decreased
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expression of hepatic FXR is associated with an increased expres-
sion of LXRs, SREBP-1c, and hepatic TAG synthesis [207]. Consis-
tent with this, activation of FXR by bile acids or synthetic FXR
agonists lowers plasma TAGs by repressing hepatic SREBP-1c
expression and also by increasing hepatic FA oxidation [208,209].
To date, there is no evidence that changes in cellular redox
status or radical compounds may directly modulate the FXR
signaling pathway. However, it was reported that the oxysterol
22-HC activates FXR (and not LXRs), inducing the expression of the
bile salt export pump, accounting for the secretion of bile acids
from the liver (Fig. 4) [210]. This ﬁnding suggests that oxysterols
may act as dual ligands that regulate both LXR and FXR target
genes in NAFLD, in a complementary pathway aimed at removing
excess cholesterol. A support for the cross talk is provided by the
demonstration that NRF2 activation improves experimental stea-
tosis by both LXR inhibition and FXR activation and that in human
NAFLD the transcript levels of LXRα and SREBP-1 are inversely
correlated with those of NFE2L2 and FXR [197].
Hepatic lipotoxicity: from low to high redox imbalance
The progression of simple steatosis to NASH may be the result
of hepatic lipotoxicity caused by an excess of FAs, which may
induce excessive ROS production and consequent cellular dysfunc-
tion and death through apoptosis and/or necrosis [211,212]. In fact,
hepatocytes overwhelmed by FAs (in particular saturated) activate
a variety of intracellular responses resulting in lipotoxic stress in
both mitochondria and endoplasmic reticulum [213].
Mitochondrial FA oxidation is still functional in NAFLD patients
presenting with simple steatosis or steatohepatitis [214]. We
observed an increased rate of mitochondrial substrate oxidation
during the early setting of liver injury in a NASH model, followed
by an impairment of mitochondrial function and increased oxida-
tive stress, despite the adaptive uncoupling mechanism, as the
disease progresses [10,12]. Moreover, the enhanced mitochondrial
oxidative metabolism in humans with high intrahepatic triglycer-
ides provides a potential link with oxidative stress and liver
damage [38]. Studies performed on liver cells tried to identify
the mechanisms of mitochondria-mediated lipotoxicity and
demonstrated that saturated FA excess enhanced TCA cycle ﬂuxes
with consequent increase in mitochondrial ROS production and
apoptosis [48], whereas exposure to a lipid emulsion triggered
excess of mitochondrial ROS leading to necrosis but not apoptosis
[215]. The role of cholesterol accumulation in the induction of
mitochondrial oxidative stress through GSH depletion sensitizing
hepatocytes to proinﬂammatory cytokines has been previously
cited [56].
An excess of saturated FAs in hepatic cell lines impairs TAG
synthesis in the ER, probably because of the formation of lipid
intermediates that induce ER stress with accumulation of unfolded
or misfolded proteins [216]. This causes the so-called unfolded
protein response (UPR), activating an intracellular signaling cas-
cade that leads to an increased transcription of ER-resident
chaperones and a decreased overall protein synthesis [212].
A human study demonstrated that the UPR is activated to varying
degrees in NAFLD liver [217], and its signaling pathway was linked
to lipid and membrane biosynthesis, insulin action, inﬂammation,
and apoptosis [218]. Under normal conditions, the redox environ-
ment in the ER lumen is different from that of other cell organelles
and favors disulﬁde formation for protein folding and assembly,
indicating that ROS formation and oxidative stress are integral
components of the UPR [219]. Oxidative stress during ER disrup-
tion may be the result of an enzymatic mechanism or of GSH
depletion [220]. Moreover, accumulation of unfolded proteins in
the ER may generate mitochondrial ROS production through Ca2þ
release and depolarization of the inner membrane [221]. Thus, the
ER-stress-induced oxidative stress and UPR triggered by altered
lipid metabolism are closely related in the progression of NAFLD
and may represent another interesting therapeutic target.
Antioxidant defense mechanisms and lipid metabolism in
NAFLD
The liver is richly endowed with antioxidant defense mechan-
isms, which include chemicals such as GSH, vitamins C and E, and
enzymes such as SOD, CAT, glutathione peroxidase (GPX), glu-
tathione S-transferase (GST), glutathione reductase (GRx), perox-
iredoxins, and thioredoxins [222].
Several lines of evidence indicate that the antioxidant defense
mechanisms are altered in NAFLD even though the results are
controversial. The hepatic glutathione content and SOD activity
were decreased in patients presenting with liver steatosis and
exacerbated in those with steatohepatitis [223]. An animal study
on fa/fa mice fed a high-fat diet conﬁrmed the reduction of hepatic
glutathione as well as GRx, GPX, SOD, and CAT activity [224].
In contrast, the activity of Cu2þ/Zn2þ-SOD, CAT, and GPX was
markedly elevated in the liver of NAFLD patients, as well as SOD
and CAT gene expression [99,225]. Another study showed that the
expression of NAD(P)Q:quinone oxidoreductase 1 and GST was
increased and related to the progression of NAFLD [226]. This
report also suggested that the antioxidant response to NAFLD
progression was induced by NFE2L2 activation [226].
A persistent condition of increased ROS induces antioxidant
gene expression through the activation of the antioxidant-
response element, primarily regulated by NFE2L2 [227,228]. Very
interestingly, NFE2L2 plays an important role in energy regulation,
because its activation induces a larger cluster of genes associated
with lipid metabolism [229]. This was also conﬁrmed by gene
disruption studies, which evidenced altered expression of genes
involved in metabolic pathways as well as exacerbation of NAFLD
in NFE2L2-knockout mice [230,231]. In contrast, enhanced expres-
sion of NFE2L2 attenuated liver steatosis in MCD-fed mice,
probably increasing hepatic antioxidant and detoxiﬁcation capa-
city, but also by inhibition of lipid deposition and expression of
CD36 and PPARα [232]. Chemically activated NFE2L2 decreased
obesity induced by a high-fat diet, but also lipid accumulation and
synthesis (through inhibition of FAS and ACC gene expression) in
liver [233]. However, even though it is conceivable that NFE2L2
negatively regulates lipid metabolism [234], targeted knockout of
NFE2L2 in adipose tissue resulted in reduction of adipogenesis by
inhibition of PPARγ [235], suggesting that the modulatory role of
this nuclear factor on lipid metabolism could be tissue speciﬁc.
Very interestingly, genetically obese mice with constitutive activa-
tion of NFE2L2 showed impaired glucose tolerance and insulin
resistance, together with reduced expression of PPARγ and SREBP-
1c in skeletal muscle and decreased lipid accumulation in white
adipose tissue, but induced NAFLD [236]. Taken together, all these
results indicate a close connection between antioxidant signaling
and lipid metabolism, even though several aspects of this network
need to be further investigated.
Antioxidant therapy in NAFLD
Because several antioxidants may favorably inﬂuence the cellu-
lar redox environment and consequently the molecular mechan-
isms implicated in NAFLD, the use of such compounds may be
beneﬁcial in the treatment of hepatic steatosis, as the redox
imbalance plays a major role in its early pathogenesis, preceding
insulin resistance and lipid metabolism alterations [237].
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This hypothesis is supported by considerable in vitro and in vivo
evidence. Experimental data demonstrate the effects of some
antioxidants in the beneﬁcial modulation of both redox status and
lipid metabolism in liver through the involvement of speciﬁc NRs.
Carnitine and carnitine–lipoic acid prevent lipotoxicity by increas-
ing mitochondrial β-oxidation and reducing intracellular oxidative
stress through PPARγ and CPT1 upregulation [238]. The antioxidant
effect of L-carnitine on human hepatocytes has also been associated
with an involvement of PPARα [101]. α-Lipoic acid (ALA) activates
both sirtuin 1—a longevity-associated protein that regulates energy
metabolism and life span in response to nutrient deprivation—and
AMPK, leading to lipid-lowering effects [239]. Moreover, ALA
reduces hepatic steatosis by downregulating SREBP-1c and ACC
[240]. The polyphenolic compound silybin, widely used as a
hepatoprotectant, is effective in the prevention of mitochondrial
dysfunction and oxidative stress in an animal model of NAFLD [241].
Moreover, it exerts antisteatotic effects because of changes in liver
expression of key enzymes involved in lipid homeostasis [242].
Geniposide shows protective effects against hepatic steatosis in rats
fed a high-fat diet owing to its antioxidant actions and as a
regulator of PPARα expression [243]. Resveratrol decreases NAFLD
severity in rats through its antioxidant activities but also AMPK
activation [244,245]. Green tea extracts protect against liver damage
in ob/ob mice but with different effects on adipogenesis and hepatic
antioxidant defenses [246,247]. Oxysterols are also considered to be
potential candidates for the treatment of NAFLD. Even though they
induce proinﬂammatory mechanisms in vitro [248], 27-HC admin-
istration can reduce hepatic inﬂammation and modulate intracel-
lular cholesterol distribution in a rodent model through LXR
modulation [249]. It was demonstrated that 5-cholesten-3β-25-
diol-3-sulfate, which is synthesized by the cytosolic sulfotransferase
SULT2B1b through sulfation of 25-HC, decreases serum and hepatic
lipid levels in a mouse model, possibly by inhibiting the LXRα/
SREBP-1c signaling pathway and by counteracting the action of its
precursor 25-HC. All this suggests that this molecule is a viable
candidate for NAFLD treatment [250]. FXR agonists may also prove
clinically useful for treating hepatic steatosis [251]. Treatment with
obeticholic acid—a ﬁrst-in-class selective FXR agonist—protects
against hepatic fat deposition together with decreased expression
of genes involved in lipogenesis [252]. However, to date there are
no reports on a possible antioxidant effect of FXR activation in liver.
Despite this large number of experimental studies encouraging
the use of antioxidant therapy in the treatment of NAFLD, there are
few clinical trials that support the efﬁcacy of these compounds.
Several studies evaluated the potential of vitamin E in the treat-
ment of NAFLD. Early pilot studies provided conﬂicting results:
vitamin E treatment caused a reduction in serum aminotransferase
activity in children [253] and improved liver pathology in adults
affected with NAFLD [254], but other studies have not demon-
strated any beneﬁt either in children or in adults [255,256].
In recent times, a study on pediatric NASH patients demonstrated
that vitamin E treatment improved ballooning and NASH activity
score, but the treatment had no effect on liver ﬁbrosis or portal
and lobular inﬂammation [257]. Another recent study on adults
has shown that vitamin E improves serum transaminase levels and
reduces hepatic steatosis and lobular inﬂammation, but is unable
to improve liver ﬁbrosis [258]. Overall, the data on the use of
vitamin E alone in the treatment of NAFLD indicates that, at least
in the early stages of the disease, vitamin E may improve serum
biochemical tests and some histological features of NASH. How-
ever, there is no deﬁnitive evidence that vitamin E improves
hepatic histology in humans, such as portal inﬂammation and
ﬁbrosis. Thus, it seems that vitamin E alone is insufﬁcient for full
treatment of NAFLD [259]. The combination of vitamins E and C
improved liver ﬁbrosis in a small trial [260], but this ﬁnding was
not subsequently conﬁrmed in a study on NAFLD children [261].
The complex formed by silybin–phospholipid–vitamin E has been
tested in NAFLD patients showing an improvement in liver
enzyme levels, hyperinsulinemia, and indexes of liver ﬁbrosis in
treated individuals [262]. Some hepatoprotective drugs such
pentoxyﬁlline, ursodesoxycholic acid, and betaine show beneﬁcial
effects improving antioxidant status, aminotransferase level,
serum ﬁbrosis markers, and metabolic parameters in NASH
patients [263–265]. Finally, a recent meta-analysis concluded that
there are insufﬁcient data to either support or refute the use of
antioxidant supplements for patients with NAFLD [266].
There could be various reasons extensive efforts in evaluating
the beneﬁts and harmful effects of antioxidant supplements in
NAFLD resulted in neutral or detrimental results. First of all, it is
likely that oxidative stress is not the only pathogenetic mechanism
contributing to liver damage in NAFLD; thus antioxidant efﬁcacy
should be investigated as a cotreatment with other drugs. On one
side there is a need for large, well-designed, randomized, double-
blind, controlled trials, with well-deﬁned endpoints, various
dosages, and proven biomarkers that correlate well with clinical
outcome and ideally also provide insights into the mechanism of
their action. Moreover, the available antioxidative compounds
present with nonselective effects [267]; this encourages carrying
out tests for targeted compounds, such as selective molecule and
nanocarrier technology. Finally, several scientists agree with the
small commitment of the pharmaceutical industry in funding
these studies, probably because antioxidants are not expensive
and modestly effective after a short-term use. Hence, we need
more extensive prospective randomized clinical trials on this topic,
mainly supported by public funding agencies.
Concluding remarks
The onset of NAFLD is characterized by changes in the hepato-
cellular redox status that lead to impaired regulation of lipid
metabolism. On the other hand, alterations in lipid metabolism
modify the redox state of the liver, which in turn may lead to
several modiﬁcations such as mitochondrial dysfunction, periph-
eral insulin resistance, and fat accumulation, perpetuating the liver
injury. The molecular mechanisms accounting for these alterations
are not completely understood, but involve redox modiﬁcation of
enzyme activity and expression, post-translational modulation,
and activation of NRs with consequent modiﬁcation of the meta-
bolic network. This evidence suggests that the pathogenesis of
NAFLD is redox-centered. Thus, the identiﬁcation of redox-
dysregulated NRs as targets for the treatment of NAFLD is a
promising approach. The impact of modulation of several NRs by
use of direct agonists/antagonists might be far from beneﬁcial,
because of the lack of a full understanding of the molecular
mechanisms of these receptors as well as lack of tissue speciﬁcity.
Because antioxidant molecules favorably modulating the cellular
redox environment may also regulate NRs known to play a role in
lipid metabolism, ﬁne-tuning of the redox status might be effec-
tive in the restoration of the signaling pathways that lead to the
development and progression of fatty liver.
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